Selective inhibitors of nuclear export for the treatment of non-Hodgkin's lymphomas

Asfar S. Azmi,[1] Ayad Al-Katib,[2] Amro Aboukameel,[3] Dilara McCauley,[4] Michael Kauffman,[4] Sharon Shacham,[4] and Ramzi M. Mohammad[3,5]

[1]Department of Pathology, [2]Department of Internal Medicine, Wayne State University, Detroit MI, USA; [3]Department of Oncology; Karmanos Cancer Institute, Wayne State University, Detroit MI, USA; [4]Karyopharm Therapeutics, Natick MA, [5]Hamad Medical Corporation, Doha, Qatar

 doi:10.3324/haematol.2012.074781



Online Supplementary Figure S1. Structure of KPT-SINEs.



S2. NCI 60 cell line screening data of KPT-SINE. Data of KPT-127 against a panel of 60 cell lines showing high potency with IC50s ranging between 5 nM to 2.5 µM. We also tested normal peripheral lymphocytes, NIH-3T3 cells and fibroblasts that were non-responsive and had IC50s in high micro molar range (>20 µM)

Online Supplementary Figure S2.



Online Supplementary Figure S3. KPT-SINE activates p53 in WSU-FSCCL (wt-p53) and p73 signaling in WSU-DLCL2 (mut-p53) cell lines. (A) mRNA expression was evaluated using real time PCR on RNA isolated from KPT-185 (10-50 nM 24 h) treated WSU-FSCCL and WSU-DLCL2 cells according to published methods. (B) Western blot analysis on whole cell lysates isolated from WSU-FSCCL and WSU-DLCL2 treated cells under similar treatment conditions. Note activation of p53 signaling in the wt-p53 cell line and p73 signaling activation in the mut-p53 cell line.